MX2021009383A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents

Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Info

Publication number
MX2021009383A
MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A
Authority
MX
Mexico
Prior art keywords
methods
lysosomal storage
storage diseases
disorders associated
treating symptoms
Prior art date
Application number
MX2021009383A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Patrick Somerville Crawford
Tanya Zaremba Fischer
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2021009383A publication Critical patent/MX2021009383A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009383A 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. MX2021009383A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US202062962647P 2020-01-17 2020-01-17
PCT/US2020/016441 WO2020163245A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Publications (1)

Publication Number Publication Date
MX2021009383A true MX2021009383A (es) 2021-09-10

Family

ID=69743942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009383A MX2021009383A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2021009384A MX2021009384A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009384A MX2021009384A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Country Status (13)

Country Link
US (2) US20220016092A1 (cg-RX-API-DMAC7.html)
EP (2) EP3920913A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022520747A (cg-RX-API-DMAC7.html)
KR (2) KR20210123352A (cg-RX-API-DMAC7.html)
CN (2) CN113645969A (cg-RX-API-DMAC7.html)
AU (2) AU2020217659B2 (cg-RX-API-DMAC7.html)
BR (2) BR112021015099A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128039A1 (cg-RX-API-DMAC7.html)
IL (3) IL313808B1 (cg-RX-API-DMAC7.html)
MX (2) MX2021009383A (cg-RX-API-DMAC7.html)
SG (2) SG11202107844UA (cg-RX-API-DMAC7.html)
TW (2) TWI865485B (cg-RX-API-DMAC7.html)
WO (2) WO2020163244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (cg-RX-API-DMAC7.html) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Also Published As

Publication number Publication date
TW202045168A (zh) 2020-12-16
MX2021009384A (es) 2021-09-10
CA3128041A1 (en) 2020-08-13
TW202508582A (zh) 2025-03-01
IL285304B1 (en) 2025-06-01
AU2020217659A1 (en) 2021-08-26
IL313808B1 (en) 2026-05-01
JP2022519274A (ja) 2022-03-22
SG11202107844UA (en) 2021-08-30
AU2020217659B2 (en) 2025-04-17
BR112021015099A2 (pt) 2021-10-05
TW202045167A (zh) 2020-12-16
SG11202107842QA (en) 2021-08-30
IL285304B2 (en) 2025-10-01
CA3128039A1 (en) 2020-08-13
IL285187B1 (en) 2026-06-01
US20220016092A1 (en) 2022-01-20
WO2020163245A1 (en) 2020-08-13
AU2020218496B2 (en) 2024-12-19
CN113710249A (zh) 2021-11-26
IL313808A (en) 2024-08-01
KR20210123352A (ko) 2021-10-13
KR20210123353A (ko) 2021-10-13
AU2020218496A1 (en) 2021-08-26
TWI865485B (zh) 2024-12-11
BR112021015172A2 (pt) 2021-09-28
US20220023273A1 (en) 2022-01-27
IL285187A (en) 2021-09-30
EP3920914A1 (en) 2021-12-15
JP7511567B2 (ja) 2024-07-05
JP2022520747A (ja) 2022-04-01
JP2025072556A (ja) 2025-05-09
WO2020163244A1 (en) 2020-08-13
CN113645969A (zh) 2021-11-12
EP3920913A1 (en) 2021-12-15
IL285304A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
BR112013031510A2 (pt) [1,3]oxazinas
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
NZ602510A (en) Treatment of lupus nephritis using laquinimod
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
MX2012012952A (es) Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina.
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
NZ602777A (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
PH12021553248A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
WO2020219486A9 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof